Page 59 - Merck Sharp News Today

COPENHAGEN, Denmark, Sept. 21, 2022 -- Evaxion Biotech A/S , a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, reached an important milestone... | September 21, 2022

Researchers are conducting a phase 2 trial to evaluate combination pembrolizumab and olaparib in BRCA-mutated/HDR-defect advanced breast cancer.

Adjuvant pembrolizumab could be a new standard of care for patients with clear cell RCC at increased risk of recurrence after nephrectomy.

To pursue discovery from foreign entities, litigants often request letters rogatory (or letters of request for judicial assistance) from a U.S. judicial authority, such as the district court...

Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically...

13.09.2022 - Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically recurrent prostate cancer Cash runway extends into fiscal third quarter of 2024 MONMOUTH ...

The dynamics of the complicated urinary tract infection market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across

Pfaff is a straggler from the In re Propecia (Finasteride) Products Liability Litigation MDL, most of which settled in 2019. The plaintiffs in Pfaff…

Olaparib maintenance can provide a clinical benefit for up to 7 years in patients with BRCA-mutated, advanced ovarian cancer, new data suggest.

Data after 24 weeks of treatment with bimekizumab in patients with axial spondyloarthritis show good responses overall regardless of prior experience with a tumor necrosis factor inhibitor.